|
 |
|
|
Immunomedics (IMMU) is focused on the targeted treatment of cancer. |
|
|
Released on Tuesday, June 5, 2012, 8:45 PM ET
Pittsburgh, PA (SpeculatingStocks) - Immunomedics (NASDAQ:IMMU) is gaining some momentum in both their therapeutic pipeline and within their stock chart. On Monday, June 11th, the company will be presenting at the 2012 Annual Meeting of the American Society of Clinical Oncology in Chicago, IL.
IMMU will be presenting on 1) their Phase I/II study of 90Y-clivatuzumab tetraxetan (90Y-hPAM4) combined with gemcitabine (Gem) in advanced pancreatic cancer (APC) and 2) therapy of human solid tumor xenografts with CD74-targeted milatuzumab-SN-38 immunoconjugates.
IMMU just reported final survival data from their two-part pancreatic cancer study with yttrium-90-labeled clivatuzumab tetraxetan combined with gemcitabine. The combination, in repeated cycles, extended survival in patients with advanced, inoperable, pancreatic cancer. The medium overall survival of 9.3 months, compared favorably with other regimens for advanced pancreatic cancer.
The company has developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents.
IMMU has approximately 199 patents issued in the US and more than 400 foreign patents, protecting their product candidates and technologies. The stock has been climbing from a double bottom at around $3.25, currently trading at $3.41 and a 52-week high of $4.32.
Find more stocks on the SpeculatingStocks homepage.
Comments:
|
|
